PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting

Print E-mail
Thursday, 06 March 2014 12:01
KNOXVILLE, Tenn.-- Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that data will be presented by researchers from Moffitt Cancer Center in a poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Read more...
 

Pluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude Mutual Investment of $10.4 million

Print E-mail
Tuesday, 17 December 2013 18:56
HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) today announced that pursuant to the previously announced exclusive out-license and strategic partnership agreement between Pluristem Ltd. and South Korea-based CHA Bio&Diostech (Kosdaq:CHA), the details of which were announced on June 26, 2013.
Read more...
 

Pluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude Mutual Investment of $10.4 million

Print E-mail
Tuesday, 17 December 2013 18:56
HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) today announced that pursuant to the previously announced exclusive out-license and strategic partnership agreement between Pluristem Ltd. and South Korea-based CHA Bio&Diostech (Kosdaq:CHA), the details of which were announced on June 26, 2013.
Read more...
 

CEL-SCI AND ERGOMED SIGN CO-DEVELOPMENT AND PROFIT SHARING AGREEMENT FOR MULTIKINE IN HIV/HPV COINFECTED WOMEN WITH CERVICAL DYSPLASIA

Print E-mail
Tuesday, 15 October 2013 07:49

Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin Inj.”) in HIV/HPV co-infected women with cervical dysplasia.  Human Papilloma Virus (HPV) is the most common sexually transmitted disease. 

Read more...
 

Pluristem Receives Israeli Ministry of Heath Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel

Print E-mail
Wednesday, 02 October 2013 07:38
HAIFA, Israel--Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Israeli Ministry of Health has approved the company’s request to initiate a Phase II study using its PLacental eXpanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD).
Read more...
 

Why services like GCP auditing are important

Print E-mail
Wednesday, 18 September 2013 07:56
Good Clinical Practice or GCP auditing is an important step in the pharmaceutical, biotechnology and device industries product development chain.
Read more...
 

FDA Lifts Clinical Hold of Pluristem’s Phase II Intermittent Claudication Study

Print E-mail
Monday, 16 September 2013 07:54
HAIFA, Israel--Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on the Company’s U.S. Phase II Intermittent Claudication (IC) study (IND 15038) on June 4, 2013.
Read more...
 

Pluristem Awarded a $3.3 Million Grant by Israeli Government

Print E-mail
Tuesday, 06 August 2013 11:17
HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 12 million New Israeli Shekels (approximately $3.3 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy.
Read more...
 

Pluristem Enters into Strategic Partnership and Licensing Agreement with Cha Bio&Diostech for the Development and Commercialization of PLX cells for the Treatment of CLI and IC in South Korea

Print E-mail
Wednesday, 26 June 2013 18:39

HAIFA, ISRAEL, June 26, 2013 --Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license and strategic partnership agreement with Cha Bio&Diostech  (Kosdaq:CHA) for the use of Pluristem’s PLacental eXpanded (PLX) cells for peripheral artery disease (PAD), specifically in two indications: the treatment of Critical Limb Ischemia (CLI), and Intermediate Claudication (IC) in South Korea.

 

Read more...
 

CEL-SCI and Northeast Ohio Medical University Develop Novel Cancer Vaccine That Prevents and Treats Breast Cancer

Print E-mail
Thursday, 31 January 2013 09:21

VIENNA, Va.--CEL-SCI Corporation (NYSE MKT: CVM) announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 134
BioMedReports Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Targeted Medical Pharma Completes Middle ... http://t.co/ia50TaWnPa
12hreplyretweetfavorite
BioMedReports Key milestone for brown fat research with a ground-breaking MRI scan http://t.co/MQTeFGrMOj
BioMedReports Baxter Announces Primary Efficacy Endpoint for Phase 3 Trial of BAX 11; Cleveland Biolabs Successfuly Close of... http://t.co/vhI1HwOLoB
navigation
Benzinga.com supporter Seeking Alpha Certified